Skip to main content
. 2020 Dec 7;6(2):414–428. doi: 10.1016/j.ekir.2020.11.026

Table 2.

Baseline laboratory parameters in the GRACE-IgANI cohort

Hemoglobin, g/dl, mean±SD (evaluable patients) 12.12±2.06 (201)
Serum total protein, g/dl, mean±SD (evaluable patients) 6.85±0.7 (198)
Serum albumin, g/dl, mean±SD (evaluable patients) 4±0.56 (198)
24-h urine protein, g/d, median (IQR) (evaluable patients) 1.9 (1–3.75) (200)
Serum total cholesterol, mg/dl, mean±SD (evaluable patients) 176.88±57.12 (198)
Serum uric acid, mg/dl, mean±SD (evaluable patients)) 7.02±1.88 (199)
Serum creatinine, mg/dl, mean±SD (evaluable patients) 2.1±1.06 (201)
eGFR MDRD, ml/min per 1.73 m2, median (IQR) (evaluable patients) 36 (24–60.5) (201)
eGFR CKD-EPI, ml/min per 1.73 m2, median (IQR) (evaluable patients) 36 (26–67.5) (201)

CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; GRACE-IgANI, Glomerular Research And Clinical Experiments–IgA Nephropathy in Indians; MDRD, Modification of Diet in Renal Disease; SD, standard deviation.